PathMaker Neurosystems is Named as Finalist for the Innovation Prize 2016
Boston, MA and Paris, France (July 26, 2016) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing non-invasive neurotherapy systems for the treatment of patients with neuromotor disorders, has been named as a Finalist for the Innovation Prize 2016 in the global competition that offers “a glimpse of the future of life sciences.”
The international competition, which was started in 2009 by Universal Biotech, honors the world’s most innovative startups and the best research academic groups that are “developing cutting edge technologies in the field of life sciences.” Of the 259 entrants from 38 countries in 2016, PathMaker was selected after two evaluation rounds as one of just seven Finalists — analyzed according to scientific quality of the innovation, intellectual property, quality of the human resources, project feasibility and market access strategy. The entrants included applications from the Biotech, Medtech, e-health and diagnostics segments of the life sciences field. The jury includes leading and prominent experts from major healthcare companies, pharmaceutical companies, biotechnology societies, and legal firms with extensive experience reviewing new technologies.
PathMaker is developing breakthrough non-invasive systems that treat patients suffering from neural pathway disruptions such as stroke, cerebral palsy, multiple sclerosis, Parkinson’s disease, traumatic brain injury and spinal cord injury. There are more than 48 million affected patients in the U.S., Europe, and China alone with these conditions. PathMaker’s first product, MyoRegulator™, provides a breakthrough non-invasive treatment for muscle spasticity and is now in IRB-approved human clinical trials. The company’s second product, MyoAmplifier™, provides an advanced non-invasive platform that treats paralysis and muscle weakness.
“At PathMaker, we are honored and excited to have been named a Finalist for this prestigious international competition,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “With the team, technology and story that we have brought together, we are working to as rapidly as possible bring our non-invasive technology to the patients who need it.”
The Innovation Prize awards will be announced during Innovation Days, an international innovation event that gathers the main actors in the Life Sciences field. It will be held on October 3-4, 2016, at the Maison de la Chimie in Paris, and more information is available here.
About PathMaker Neurosystems Inc.
PathMaker Neurosystems Inc. is a clinical-stage neurotechnology company developing non-invasive neurotherapy systems based on Coordinated Multi-Site Neurostimulation. With offices in Boston (US) and Paris (France), PathMaker is moving forward a trans-Atlantic strategy to rapidly bring to market entirely novel, breakthrough approaches to non-invasively treating neuromotor disorders. More than 48 million patients in the US, Europe and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. At PathMaker, we are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions. Visit the company website at www.pmneuro.com.
Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, email@example.com